πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 635 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11254655

Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11254669

Fused imidazo-piperidine JAK inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11247969

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11230536

Crystalline (2S,4R)-5-(5β€²-chloro-2β€²-fluoro-[1,1β€²-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hyd

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11174219

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11160810

Fused imidazo-piperidine JAK inhibitor compound

Theravance Biopharma R&D IP, LLC Β· Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11160800

Methods of treatment using a JAK inhibitor compound

Theravance Biopharma R&D IP, LLC Β· Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11155549

Ester and carbonate pyrimidine compounds as JAK kinase inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11124502

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11110095

Pyrimidine compounds as JAK kinase inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11033533

(2R,4R)-5-(5β€²-chloro-2β€²-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amin

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11008289

Crystalline freebase forms of a biphenyl compound

Theravance Biopharma R&D IP, LLC Β· Granted Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10988470

Pyrimidine compound as JAK kinase inhibitor

Theravance Biopharma R&D IP, LLC Β· Granted Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10968222

2-azabicyclo hexane JAK inhibitor compound

Theravance Biopharma R&D IP, LLC Β· Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10968205

Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10961267

Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory diseas

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10952996

ALK5 inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10954237

JAK inhibitors containing a 4-membered heterocyclic amide

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10947254

Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10946007

4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10946006

Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10946009

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10913740

JAK kinase inhibitor compounds for treatment of respiratory disease

Theravance Biopharma R&D IP, LLC Β· Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10851102

Imidazole and triazole containing bicyclic compounds as JAK inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted